Please login to the form below

Not currently logged in
Email:
Password:

GSK to build research centres in Shanghai

GSK has said it will spend USD 40m on the construction of a research facility in Shanghai which will eventually be one of its largest global research centres

According to local media reports, GlaxoSmithKline (GSK) will spend USD 40m (EUR 29.4m) on the construction of a research facility in Shanghai which will eventually be one of its largest global research centres.

GSK is looking for a research facility location in the city and aims to recruit 50 to 100 top international scientists.

Amy Huang, president of GSK operations on the Chinese mainland and Hong Kong, told state-owned press agency, China Daily, that China would not only be famous as the world's factory, but also attract global attention to its research and development for the pharmaceutical industry.

Other pharmaceutical majors include Novartis, which revealed back in November 2006 that it would build its eighth global research centre in China at an investment of USD 100m.

Three months ago, US pharmaceutical company Elli Lilly committed USD 100m (EUR 73.4m) for research in China. It also established a venture fund to invest in domestic drug developers, including a first investment of USD 10m (EUR 7.3m) in an unnamed local firm.

Perry Nisen, senior vice-president of clinical pharmacology and discovery medicine was reported as saying that the most important factor is access to scientific talent.

GSK had been investigating centres in India and South Korea, but finally selected Shanghai due to its number and quality of universities and hospitals and the density of foreign drug makers in the city, as well as its attraction to overseas scientists.

The GSK centre will be the only one for the company focusing on neurodegenerative disorders like Parkinson's disease, Alzheimer's disease and multiple sclerosis.

4th July 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Dr Henry Skinner
The AMR Action Fund is combating antimicrobial resistance, but much more action is needed
By Henry Skinner, Chief Executive Officer of the AMR Action Fund...
Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...